Compound library / Fat Loss / GLP-1
Dual GIP/GLP-1 receptor agonist, FDA-approved (Mounjaro/Zepbound) for type 2 diabetes and weight management.
| Category | Fat Loss / GLP-1 |
|---|---|
| Typical route | Subcutaneous |
| Half-life | ~5 days |
| Common dose range | 2.5-15 mg/week, titrated |
| Typical cycle length | Ongoing under medical supervision |
BioHack Track models Tirzepatide at a half-life of 120 hours, so every dose you log is decayed against that curve and the app shows what is still circulating — not just what you typed.
Typically supplied pre-filled; compounded versions require reconstitution per pharmacy instructions.
Refrigerate; some pens stable at room temp short-term per label.
Prescription medication — requires medical supervision. GI side effects common; same thyroid C-cell tumor warning as other GLP-1/GIP drugs.
Track Tirzepatide in BioHack Track. Half-life, dose range and route come pre-filled from this library — log a dose and the app counts your vial down, models what is in your system, and puts it on the same chart as your labs and body composition.
These open a search of each database for Tirzepatide — they are not citations, and nothing here is evidence for any particular dose. The same links are in the app.
General reference compiled for use inside the app, not medical advice and not a recommendation to take anything. Dose ranges are what is commonly discussed, not a prescription. Talk to a qualified healthcare professional.